Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · Real-Time Price · USD
12.80
-1.00 (-7.25%)
At close: Dec 11, 2025, 4:00 PM EST
13.02
+0.22 (1.72%)
After-hours: Dec 11, 2025, 6:33 PM EST
Fulcrum Therapeutics Revenue
In the year 2024, Fulcrum Therapeutics had annual revenue of $80.00M with 2,752.05% growth.
Revenue (ttm)
$80.00M
Revenue Growth
+2,752.05%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
45
Market Cap
692.72M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 80.00M | 77.20M | 2,752.05% |
| Dec 31, 2023 | 2.81M | -3.54M | -55.77% |
| Dec 31, 2022 | 6.34M | -12.82M | -66.90% |
| Dec 31, 2021 | 19.16M | 10.34M | 117.19% |
| Dec 31, 2020 | 8.82M | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
FULC News
- 1 day ago - Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 3 days ago - Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock - GlobeNewsWire
- 3 days ago - Fulcrum Therapeutics Stock Rally Ignited By Promising Sickle Cell Results - Benzinga
- 4 days ago - Fulcrum Therapeutics, Inc. (FULC) Discusses New Clinical Data From the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease Transcript - Seeking Alpha
- 5 days ago - Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting - GlobeNewsWire
- 6 days ago - Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 9 days ago - Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025 - GlobeNewsWire
- 5 weeks ago - Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting - GlobeNewsWire